macitentan   Click here for help

GtoPdb Ligand ID: 7352

Synonyms: ACT-064992 | Opsumit® | Opsynvi® (combination of macitentan + tadalafil)
Approved drug
macitentan is an approved drug (FDA and EMA (2013))
Compound class: Synthetic organic
Comment: Macitentan is an endothelin receptor antagonist (ERA). It exhibits approximately 50-fold selectivity for the ETA receptor over the ETB receptor [2].
Click here for help
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: macitentan

2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 8
Hydrogen bond donors 2
Rotatable bonds 11
Topological polar surface area 136.6
Molecular weight 585.96
XLogP 4.15
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CCCNS(=O)(=O)Nc1ncnc(c1c1ccc(cc1)Br)OCCOc1ncc(cn1)Br
Isomeric SMILES CCCNS(=O)(=O)Nc1ncnc(c1c1ccc(cc1)Br)OCCOc1ncc(cn1)Br
InChI InChI=1S/C19H20Br2N6O4S/c1-2-7-26-32(28,29)27-17-16(13-3-5-14(20)6-4-13)18(25-12-24-17)30-8-9-31-19-22-10-15(21)11-23-19/h3-6,10-12,26H,2,7-9H2,1H3,(H,24,25,27)
InChI Key JGCMEBMXRHSZKX-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
Macitentan is approved for the treatment of pulmonary arterial hypertension (PAH).
In March 2024 the FDA approved a single pill combination of macitentan and the phosphodiesterase 5 (PDE5) inhibitor tadalafil (Opsynvi®), for the chronic treatment of PAH.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Macitentan is an endothelin receptor antagonist. It blocks endothelin-1-induced activation of endothelin A and B receptors (ETA and ETB respectively) located on blood vessels and smooth muscle, and reduces fibrosis and vasoconstriction by modulating the renin-angiotensin system.
External links Click here for help